Oxigenoterapia no invasiva en pacientes con COVID-19: wu ji bi fan: mucho de algo no es bueno.

In clinical practice, oxygen can save lives, although, wu ji bi fan: too much of something is not good and it can also cause toxicity; 14% of patients with coronavirus disease 2019 (COVID-19) will need non-invasive oxygen therapy and approximately 5% will require invasive mechanical ventilation (IMV). Noninvasive oxygen therapy is the first-line treatment for patients with hypoxemic acute respiratory failure secondary to COVID-19. The devices through which this therapy is administered can be classified into low flow and high flow. In the presence of acute hypoxemic respiratory failure, the necessary flow can be 30 to 120 L/min, a number that cannot be achieved with conventional systems (low flow), therefore, high-flow devices can be effective in well-selected patients, the aim is to improve oxygenation, avoid orotracheal intubation of the patient, but without delaying it. Noninvasive oxygen therapy does not increase the risk of aerosol infection. [ABSTRACT FROM AUTHOR]